AstraZeneca Pharma India and Sun Pharmaceutical Industries have entered a second brand partnership to expand the availability of sodium zirconium cyclosilicate (SZC) in India. The agreement aims to accelerate patient access to the therapy, an innovative treatment for hyperkalaemia.
Under the collaboration, both companies will promote, market and distribute SZC under separate brand names:
AstraZeneca will retain intellectual property rights, hold the marketing authorization, and maintain the import licence for the molecule.
Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, said the partnership supports the company’s strategy to expand early screening, diagnosis and guideline-directed therapy.
He noted that broader access to SZC could help address the national disease burden associated with hyperkalaemia.
Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries, said the collaboration strengthens Sun Pharma’s commitment to improving care for patients with chronic kidney disease. He added that incorporating SZC into Sun Pharma’s portfolio supports the company’s focus on expanding access to innovative therapies.
Hyperkalaemia is a potentially serious condition often seen in patients with chronic kidney disease or heart failure, particularly those receiving RAAS inhibitor therapy, which can raise serum potassium levels.
Sun Pharma remains the largest pharmaceutical company in India, holding an 8.3% market share. The company ranks first in prescriptions across 13 medical specialties and maintains a strong presence in both chronic and acute therapy areas, supported by a field force of over 15,000.
AstraZeneca noted that the collaboration aligns with its broader ambition to advance science and enhance management of life-threatening conditions such as hyperkalaemia. The companies said the partnership is expected to improve availability of SZC nationwide and support better patient outcomes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!